Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Edward Kaye, MD, Sarepta’s interim chief executive officer and chief medical officer will provide a corporate update and report on recent data from the Phase IIb study of eteplirsen for Duchenne muscular dystrophy via a live webcast and conference call on October 1, 2015 at7:00 AM EST. The update will be followed by a panel discussion with Duchenne muscular dystrophy experts Anne Connolly, MD; Eugenio Mercuri, MD, PhD; Jerry Mendell, MD; Perry Shieh, MD, PhD; and Steve Wilton, PhD, BSc. (Original Source)
Shares of Sarepta Therapeutics Inc. closed yesterday at $38.88. SRPT has a 1-year high of $41.47 and a 1-year low of $11.33. The stock’s 50-day moving average is $35.67 and its 200-day moving average is $25.41.
On the ratings front, Sarepta Therapeutics has been the subject of a number of recent research reports. In a report issued on September 3, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on SRPT, with a price target of $50, which implies an upside of 28.6% from current levels. Separately, on August 26, Cowen’s Ritu Baral maintained a Hold rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Debjit Chattopadhyay and Ritu Baral have a total average return of 23.7% and 20.2% respectively. Chattopadhyay has a success rate of 61.4% and is ranked #14 out of 3764 analysts, while Baral has a success rate of 48.7% and is ranked #72.
The street is mostly Bullish on SRPT stock. Out of 8 analysts who cover the stock, 7 suggest a Buy rating and one recommends to Hold the stock. The 12-month average price target assigned to the stock is $46.00, which implies an upside of 18.3% from current levels.
Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.